The Rollings Cancer Center (HCC) is directed by Andrew S. Kraft, MD (Director) with the assistance of Anthony J. Alberg, PhD, MPH (Associate Director of Cancer Prevention &Control);Daniel J. Fernandes, PhD (Associate Director of Translational Research);Marvella E. Ford, PhD (Associate Director of Cancer Disparities);Yusuf A. Hannun, MD (Associate Director of Basic Sciences);Anita L. Harrison, MPA (Associate Director of Administration);Carolyn E. Reed, MD (Associate Director of Medical Affairs);Steven A. Rosenzweig, PhD (Assistant Director of Shared Resources);and Melanie B. Thomas, MD (Associate Director of Clinical Investigations). These experienced individuals are organized as a Senior Leadership team that represents the strong functional nexus of this matrix-based Center. Dr. Kraft has charged the members of the team with employing consensus building techniques as they work directly with the various HCC boards/councils and committees to formulate priorities, strategies and allocation of resources. The Senior Leadership team works together to ensure consistency in the vision and goals of the Center;develop synergistic interactions among the basic, translational, and clinical elements of the Center;plan proactive approaches to the development of the research base and resources;effectively leverage all available resources at MUSC and at the state and national levels;engage in community outreach;and oversee all activities of the HCC. The Senior Leadership team meets several times a month in the context of HCC's various board/committee/council meetings, one-on-one with the Director, and once a month as a formal Executive Council. They provide direct counsel and recommendations to the Director based on these interactions. All final authority for decisions on behalf of the HCC resides with the Director.
Support is requested for several members of the HCC Senior Leadership who provide counsel and recommendations to the Director as it pertains to the strategic planning and evaluation of the Center's efforts.
|Link, Laura A; Howley, Breege V; Hussey, George S et al. (2016) PCBP1/HNRNP E1 Protects Chromosomal Integrity by Translational Regulation of CDC27. Mol Cancer Res 14:634-46|
|Nelson, Michelle H; Bowers, Jacob S; Bailey, Stefanie R et al. (2016) Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer 4:6|
|Podbielska, Maria; Szulc, ZdzisÅ‚aw M; Kurowska, Ewa et al. (2016) Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. J Lipid Res 57:2028-2039|
|Sambandam, Yuvaraj; Sakamuri, Sashank; Balasubramanian, Sundaravadivel et al. (2016) RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells. J Cell Biochem 117:118-25|
|Miller, Kayla; Dixit, Suraj; Bredlau, Amy-Lee et al. (2016) Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. Nanomedicine (Lond) 11:581-95|
|Basher, Fahmin; Jeng, Emily K; Wong, Hing et al. (2016) Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. Oncotarget 7:814-30|
|Small, James; Flanagan, Catherine; Armeson, Kent et al. (2016) Family history of cutaneous and noncutaneous malignancies in relation to the risk of keratinocyte carcinoma coupled with another type of cancer: A case-control study. J Am Acad Dermatol 75:1066-1068.e7|
|Maldonado, Eduardo N; DeHart, David N; Patnaik, Jyoti et al. (2016) ATP/ADP Turnover and Import of Glycolytic ATP into Mitochondria in Cancer Cells Is Independent of the Adenine Nucleotide Translocator. J Biol Chem 291:19642-50|
|Hendriks, Giel; Derr, Remco S; Misovic, Branislav et al. (2016) The Extended ToxTracker Assay Discriminates Between Induction of DNA Damage, Oxidative Stress, and Protein Misfolding. Toxicol Sci 150:190-203|
|Paul, Matt R; Levitt, Nicholas P; Moore, David E et al. (2016) Multivariate models from RNA-Seq SNVs yield candidate molecular targets for biomarker discovery: SNV-DA. BMC Genomics 17:263|
Showing the most recent 10 out of 311 publications